OcuTerra Therapeutics Revenue and Competitors

Location

$35M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • OcuTerra Therapeutics's estimated annual revenue is currently $930k per year.(i)
  • OcuTerra Therapeutics's estimated revenue per employee is $77,500
  • OcuTerra Therapeutics's total funding is $35M.

Employee Data

  • OcuTerra Therapeutics has 12 Employees.(i)
  • OcuTerra Therapeutics grew their employee count by 20% last year.

OcuTerra Therapeutics's People

NameTitleEmail/Phone
1
CEO & PresidentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is OcuTerra Therapeutics?

Non-Invasive, Transformational Approach to Treating Retinal Disease. OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity

keywords:N/A

$35M

Total Funding

12

Number of Employees

$930k

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

OcuTerra Therapeutics News

2022-04-06 - OcuTerra Appoints Majid Anderesi, MD, as Vice President of ...

BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M120%$101.2M
#2
$1M12N/AN/A
#3
$1M12N/AN/A
#4
$1M12N/AN/A
#5
$1M12N/AN/A